A Study to Evaluate the Safety and Efficacy of ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features

Parkinson Disease Clinical Trial

Official title:

A Prospective, Randomized, Sham Controlled Study to Evaluate the Safety and Efficacy of ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03454425
• Other study ID #: PD010
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 27, 2018
• Est. completion date: March 31, 2023

Study information

• Verified date: August 2022
• Source: InSightec
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to test the efficacy and safety of unilateral subthalamotomy performed using the ExAblate System for the treatment of Parkinson's disease (PD) motor features.

Description:

A Prospective, Randomized, Sham Controlled Study to Evaluate the Safety and Efficacy of ExAblate Subthalomotomy for the treatment of Parkinson's disease motor features.

The objective of this prospective, randomized, double-blind (to subjects, examining neurologists and external video-based examination by Movement Disorders neurologist), two-arm study (ExAblate treated arm Vs ExAblate Sham treated control arm) is to confirm the efficacy of ExAblate Model 4000 Type 1 System for the treatment of Parkinson's disease (PD) motor features and to further demonstrate safety.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: March 31, 2023
• Est. primary completion date: January 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

1. Men and women age 30 years or older

2. Subjects who are able and willing to give consent and able to attend all study visits.

3. Subjects with a diagnosis of PD by UK Brain Bank Criteria as confirmed by a movement disorder neurologist at the site.

4. Predominant motor features/disability from one side of the body (i.e asymmetry index > 1.5) as determined by a movement disorders neurologist.

5. Motor clinical features non-optimally controlled by an adequate medical treatment prescription. An adequate medication prescription is defined as a therapeutic dose of each medication or the development of side effects as the medication dose is titrated.

6. No major changes in pharmacological regime for PD should be done for the 30 days prior to procedure.

7. Topographic coordinates of the subthalamic nucleus are localizable on MRI so that it can be targeted by the ExAblate device.

8. Able to communicate sensations during the ExAblate MRgFUS treatment Inclusion and exclusion criteria have been agreed upon by two members of the medical team

Exclusion Criteria:

1. Hoehn and Yahr stage in the ON medication state of 2.5 or greater

2. Presence of severe dyskinesia as noted by a score of 3 or 4 on questions 4.1 and 4.2 of the MDS-UPDRS.

3. Presence of other central neurodegenerative disease suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer's disease.

4. Any suspicion that Parkinsonian symptoms are a side effect from neuroleptic medications.

5. Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia

6. Presence of significant cognitive impairment defined as score = 21 on the Montreal Cognitive Assessment (MoCA) or Mattis Dementia Rating Scale of 120 or lower.

7. Unstable psychiatric disease, defined as active uncontrolled depressive symptoms, psychosis, delusions, hallucinations, or suicidal ideation. Subjects with stable, chronic anxiety or depressive disorders may be included provided their medications have been stable for at least 60 days prior to study entry and if deemed appropriately managed by the site neuropsychologist

8. Subjects with significant depression as determined following a comprehensive assessment by a neuropsychologist. Significant depression is being defined quantitatively as a score of greater than 14 on the Beck Depression Inventory.

9. Legal incapacity or limited legal capacity as determined by the neuropsychologist

10. Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlined in the DSM-IV as manifested by one

11. Subjects with unstable cardiac status including

12. Severe hypertension (diastolic BP > 100 on medication).

13. History of or current medical condition resulting in abnormal bleeding and/or coagulopathy.

14. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure

15. Subjects with risk factors for intraoperative or postoperative bleeding as indicated by: platelet count less than 100,000 per cubic millimeter, a documented clinical coagulopathy, or INR coagulation studies exceeding the institution's laboratory standard

16. Patient with severely impaired renal function with estimated glomerular filtration rate <30mL/min/1.73m2 (or per local standards should that be more restrictive) and/or who is on dialysis;

17. Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.

18. Significant claustrophobia that cannot be managed with mild medication.

19. Subject who weight more than the upper weight limit of the MR table and who cannot fit into the MR scanner

20. Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment.

21. History of intracranial hemorrhage

22. History of multiple strokes, or a stroke within past 6 months

23. Subjects with a history of seizures within the past year

24. Subjects with malignant brain tumors

25. Subjects with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment.

26. Any illness that in the investigator's opinion preclude participation in this study.

27. Subjects unable to communicate with the investigator and staff.

28. Pregnancy or lactation.

29. Subjects who have an Overall Skull Density Ratio lower than 0.35 as calculated from the screening CT.

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Device:
• Exablate Subthalamotomy
ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
• Sham Exablate Subthalamotomy
Sham ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features

Locations

Country	Name	City	State
Spain	Hospital Universitario HM Puerta Del Sur. CINAC	Móstoles	Madrid

Sponsors (1)

Lead Sponsor	Collaborator
InSightec

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy - MDS-UPDRS	between-group differences in the mean change (from baseline to 4 months) in the motor MDS-UPDRS score for the side contralateral to subthalamotomy (in the treated group) as compared with mean change in the MDS-UPDRS score for the side contralateral to the alleged subthalamotomy (in the sham-procedure group) in the off-medication condition	Baseline to 4 months post treatment
Primary	Safety - Adverse Events	To evaluate the incidence and severity of adverse events (AE/AEs) associated with ExAblate subthalamotomy for the treatment of PD motor features.	Baseline to 4 Months post treatment
Secondary	MDS-UPDRS III ON-medication	MDS-UPDRS III score in the contralateral body side ON-medication condition as measured by the BLINDED assessor	Baseline to Month 4 post treatment
Secondary	MDS-UPDRS III OFF-medication	MDS-UPDRS III score in the contralateral body side OFF-medication condition as measured by the UNBLINDED assessor	Baseline to Month 4 post treatment
Secondary	MDS-UPDRS III- Contralateral ON-medication	MDS-UPDRS III score in the contralateral body side ON-medication condition as measured by the UNBLINDED assessor	Baseline to Month 4 post treatment
Secondary	MDS-UPDRS III	Specific PD motor features sub-scores (rigidity, bradykinesia, tremor) of MDS- UPDRS III in the contralateral body side by visit for the following: OFF and ON-medication condition as measured by the BLINDED assessor	Baseline to Month 4 post treatment
Secondary	MDS-UPDRS II	Total score of MDS-UPDRS II	Baseline to Month 4 post treatment
Secondary	MDS-UPDRS III Blinded assessor	Total score of MDS-UPDRS III as measured by the BLINDED assessor OFF- and ON-medication	Baseline to Month 4 post treatment
Secondary	MDS-UPDRS IV	Total score of MDS-UPDRS IV and separated by each type of motor complication	Baseline to Month 4 post treatment
Secondary	PDG39	Quality of life assessment with the PDQ39.	Baseline to Month 12 post treatment
Secondary	GIC	Patient global impression of change from Baseline to Month 4 FU.	Baseline to Month 4 post treatment
Secondary	Levodopa	Levodopa equivalent medication change usage (mg).	Baseline to Month 12 post treatment
Secondary	MDS-UPDRS	Durability of the reduction in the contralateral motor MDS-UPDRS at 12 months in the treated group (measured only by the UNBLINDED assessor)	Baseline to Month 12 post treatment
Secondary	MDS-UPDRS	Change in the total MDS-UPDRS III according to disease severity at baseline (as defined by the MDS-UPDRS III score).	Baseline to Month 12 post treatment